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Measurements were performed to assess the dose equivalent outside a primary proton treatment
field, using a silicon-on-insulator 共SOI兲 microdosimeter. The SOI microdosimeter was placed on the
surface of an anthropomorphic phantom and dose equivalents were determined as a function of
lateral distance from a typical passively scattered and modulated prostate treatment field. Measurements were also completed within a polystyrene plate phantom as a function of depth for a distance
of 5 cm from the field edge, as function of lateral distance from field edge at two different depths,
and as a function of distance from the distal edge on the central beam axis. The dose equivalent at
the surface of the anthropomorphic phantom decreases from 3.9 to 0.18 mSv/Gy when the lateral
distance from the proton field edge increases from 2.5 to 60 cm. Measurements along the proton
depth dose distribution at a constant distance of 5 cm from the primary field edge indicate a
decrease in dose equivalent as a function of depth, with a 38% decrease relative to the surface dose
at a depth of 5 cm in polystyrene. Measurements completed as a function of lateral distance from
the primary field at two separate depths within polystyrene illustrate a convergence of the dose
equivalent at approximately 20 cm from the primary field edge. Past the distal edge of the spreadout Bragg peak dose equivalents decrease exponentially for increasing distance, with an initial
value of 1.6 mSv/Gy at 0.6 cm from the distal edge. Silicon microdosimetry measurements were
also compared with published results obtained utilizing different measurement techniques. This
study demonstrates the applicability of SOI microdosimetry in determining the dose equivalent
outside proton treatment fields, and provides valuable information on the dose equivalent both at
the surface and at depth experienced by prostate cancer patients treated with protons. © 2007
American Association of Physicists in Medicine. 关DOI: 10.1118/1.2759839兴
Key words: proton therapy, dose equivalent, neutrons, microdosimetry
I. INTRODUCTION
Presently one of the major health risks mankind faces is cancer. Projections are that one in three people will suffer from
this disease or side effects of its treatment at one stage in
their life.1 Because of the deleterious effects that cancer and
often current treatment forms are having on the human population, better treatment techniques are constantly being
sought. Besides surgery, external beam radiation therapy is a
mainstay of cancer treatment and cure. Over the last two
decades highly conformal radiation therapy techniques have
been developed, including intensity modulated photon radiotherapy 共IMRT兲 and radiotherapy utilizing protons and carbon ions. One drawback of these techniques is that they may
increase the contribution of lower doses to large volumes of
normal tissues outside the target volume.2
High energy protons are an important innovation in external beam radiation therapy, providing highly conformal dose
distributions, thus sparing normal tissues through the benefits
afforded by the Bragg peak. These dose distributions provide
a smaller integral dose to surrounding normal tissues when
compared with conventional x-ray treatments. Despite the
dose sparing properties of protons and heavy ions, they do
3449
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have the potential to produce unwanted dose outside the primary field due to secondary particles such as neutrons
through inelastic nuclear interactions with the beam modifying devices and tissues traversed. This is of concern as neutrons are known to be more effective than photons and high
energy protons at producing radiation induced cancers.2 The
primary beam is also scattered as it traverses the patient,
contributing additional unwanted dose outside the primary
treatment field.
The production of secondary particles with therapeutic
proton beams and the delivery of unwanted dose equivalent
outside the treatment field is closely related to the delivery
technique employed.2 Proton delivery techniques can be categorized as passive or active in the delivery of a uniform
dose to the treatment volume. Passive techniques, which
have been most commonly used in the clinical setting, including prostate cancer treatment,3,4 spread the beam laterally using a combination of gold and Lexan foils5 and in
depth by using a rotating plastic wheel.6 The beam is then
collimated by brass or Cerrobend® apertures and its penetration depth is varied by means of a wax bolus. Active
techniques,7–10 currently only practiced in a clinical situation
at the Paul Scherrer Institute 共PSI兲, employ a magnetically
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FIG. 1. Basic SOI diode array structure of the microdosimeter developed
at the CMRP, University of
Wollongong.

guided proton pencil beam in combination with dynamic
changes of beam energy and beam intensity during treatment. Comparatively, passive beam delivery techniques provide a larger source of secondary neutrons due to the additional presence of scattering foils, modulator, aperture, and
bolus.
Measurements of out-of-field doses delivered in both active and passive clinical proton modalities are scarce11–13 and
have primarily concentrated on the measurement of neutrons
with Bonner spheres and bubble detectors. Additional measurements are required and should be performed systematically for different beam delivery techniques utilizing the
same method of measurement. We have approached this
problem utilizing silicon-based microdosimetry, which is
characterized by a superior spatial resolution and directly
provides information on the dose equivalent using established quality factors.14 The measurements reported here provide information on the depth and lateral distance dependence of the dose equivalent for a passively scattered proton
beam used in a typical prostate cancer treatment. Silicon microdosimetry measurements were compared with published
results obtained utilizing different measurement techniques.
II. EXPERIMENTAL METHOD
This study utilized a solid-state microdosimeter with
silicon-on-insulator 共SOI兲 technology as illustrated in Fig. 1.
The large size of tissue equivalent proportional counters
共TEPC兲, classically used in microdosimetry measurements,15
made it unsuitable for measurements in small increments
close to the primary proton treatment field edge and within a
phantom structure. The SOI microdosimeter, presented in detail in Ref. 16, comprised an array of 4800 silicon cells, each
with a physical size of 30⫻ 30 m, on a single chip with a
sensitive volume 共SV兲 thickness of 10 m. This small size
allowed for accurate placement within the phantom structure
and close to the primary field edge. The application of SOI
microdosimeters in therapeutic neutron radiation fields has
been studied in detail, and good agreement was observed
Medical Physics, Vol. 34, No. 9, September 2007

between the derived microdosimetry spectra of both the SOI
and TEPC devices.17,18 This device has also been used extensively in hadron and proton therapy, particularly in primary beam microdosimetry measurements.16,17,19–21
In this experimental setup, the SOI microdosimeter, preamplifier, and accompanying electronics were situated within
an aluminum probe assembly to allow for a low noise environment to be achieved. The wall thickness of the probe was
900 m, with a 4 m aluminum window immediately in
front of the microdosimeter to allow for the transport of low
range secondaries into the microdosimeter. The microdosimeter probe was housed within a Perspex probe holder to enable accurate placement throughout the experiment. This
setup is described further in Ref. 21. A 0.5 mm thick polyethylene converter affixed immediately anterior to the SOI
microdosimeter allowed for the conversion of neutrons to
recoil protons that could then be detected within the SV.
Such converters have been employed in previous neutron
and mixed field measurements with this device.17,20
All measurements were completed using a patient specific
aperture-bolus combination, and proton energy of 225 MeV
to simulate a typical radiation field delivered in a clinical
prostate case. The maximum aperture diameter was 8 cm
both in lateral and vertical direction. Additional measurements were also completed in some cases using a 13 cm
diameter circular aperture 共quality assurance or QA aperture兲
with no bolus present to demonstrate the effect of aperture
size and bolus on the dose equivalent. To conduct a thorough
study of the dose equivalent delivered outside the treatment
field, four separate experimental configurations were used,
each measuring a different aspect of the radiation field. In the
first case, the patient was simulated with an anthropomorphic
phantom 共Rando® Phantom, The Phantom Laboratory, Salem, NY兲 housed within a regular patient immobilization
system 共Fig. 2兲. The microdosimeter 共MD兲 was placed on the
phantom surface at the height of the central axis, and microdosimetry measurements were performed to determine the
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FIG. 2. Experimental setup for surface measurements as a function of distance from the field edge.

change in dose equivalent as a function of increasing lateral
distance from the field edge.
Additional measurements were conducted with the anthropomorphic phantom replaced with a stack of polystyrene
blocks. Using this experimental setup, three measurement
series were completed 共Fig. 3兲. First, the MD was placed at
different depths within the polystyrene phantom at a distance
of 5 cm from the field edge to estimate the change in dose
equivalent as a function of depth within the patient 共series
M1兲. Measurements were also completed to assess the
change in dose equivalent as a function of lateral distance
from the field edge at different depths within the polystyrene
phantom 共series M2兲. Finally, measurements were completed
to assess the dose equivalent beyond the distal edge of the
spread-out Bragg peak 共SOBP兲 共series M3兲, with the distal
edge being defined as the point where the primary dose
reached 50%. In all cases, dose equivalent was normalized to
the proton dose delivered at isocenter.
II.A. Determination of dose equivalent

The dose equivalent 共H兲 was defined in Ref. 14 to characterize the effects of low doses of ionizing radiation on
health. It is defined by the ICRU as
H = QD,

共1兲

where Q is the average quality factor of the radiation field
and D is absorbed dose in tissue at a given point of interest.
The unit of dose equivalent is the Sievert 共Sv兲, with Q specified by ICRU Report 40.22
In this study, the method outlined in Refs. 14 and 15 was
used in the determination of H with specified Q values,
which are dependent on lineal energy. The conversion of
measured microdosimetry spectra 共Fig. 4兲 to dose equivalent

3451

FIG. 3. Experimental setup for experimental measurements within a polystyrene phantom. Note the three separate measurement series conducted
with this experimental setup. M1 determined the change in dose equivalent
as a function of depth; M2 provided the change in dose equivalent as a
function of distance from the field edge within the polystyrene phantom; and
M3 indicated the change in dose equivalent past the distal edge.

proceeded in two steps: 共1兲 calculation of absorbed dose to
tissue at each point of measurement; 共2兲 calculation of the
dose-averaged quality factor at that point.
Microdosimetric data were acquired as energy deposition
spectra f共E兲 vs E, where f共E兲 is the relative frequency of
events and E the energy determined from the charge collected within in a single silicon SV. Energy deposition events
were corrected for 0.8 charge collection efficiency23 and then
used to calculate the absorbed dose to silicon by integrating
over the spectrum 关Eq. 共2兲兴,
DSi =

兰⬁0 f共E兲EdE
,
SiVncells

共2兲

where ncells is the number of SVs in a given array used
共4800兲,16 V is the volume of a 30⫻ 30⫻ 10 m3 individual
detection element, and Si the density of silicon.24 The tissueequivalent 共TE兲 dose DTE can then be determined by using
the ratio of total stopping powers of protons for silicon, SSi
and tissue STE 共Ref. 25兲 共referred to in this document as TE
conversion factor 兲,
DSi SSi
=
= .
DTE STE

共3兲

From previous research16,17,19 and comparisons with TEPCs,
the most appropriate value of  was determined to be 
= 0.63, which was used in this work.
The first step in calculating the fraction of the doseaverage quality factor is to convert the f共E兲 spectra into a
lineal energy spectra using the average chord length 具l典,

FIG. 4. Examples of distributions obtained using the SOI microdosimeter
including 共a兲 f共E兲 vs E distribution;
共b兲 f共y兲 vs y distribution; 共c兲 yd共y兲 vs
y distribution.
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FIG. 6. Dose equivalent at 5 cm from the field edge compared with the depth
dose distribution of the proton beam as measured along the central axis with
a Markus chamber. The proton dose is expressed as a percentage with 100%
dose delivered at isocenter.
FIG. 5. Results as measured with the SOI microdosimeter for both the patient specific aperture/bolus portal and the 13 cm circular QA aperture with
no bolus present.

具l典 =

4V
,
A

共4兲

where V is the volume and A the surface area of the SV. For
the 30⫻ 30⫻ 10 m3 sensitive volume the average chord
length is 19.05 m. Note the use of the TE conversion factor to calculate the average chord length in tissue. Dividing E
by 具l典 in the energy deposition spectra provides the lineal
energy spectra. The normalized dose-weighted lineal energy
distribution is given by
yf共y兲
,
yf

d共y兲 =
where
yf =

冕

⬁

yf共y兲dy

共5兲

共6兲

0

is the frequency averaged lineal energy. Note that d共y兲 gives
the fraction of total absorbed dose in the interval 关y , y + dy兴.
In order to determine dose equivalent, a y-dependent quality factor Q共y兲 was introduced as prescribed by ICRU Report
40.22 From the d共y兲 distribution, the dose equivalent at that
point in space can be determined using Eq. 共7兲,
H = DTE

冕

⬁

Q共y兲d共y兲dy = QavgDTE ,

共7兲

0

where Qavg is the average quality factor.
III. RESULTS
Figure 5 presents the results of dose equivalent values on
the surface of the anthropomorphic phantom as a function of
distance from the incident proton field edge. It is evident
from these results that the aperture and bolus used within a
typical prostate cancer patient treatment increased the dose
equivalent by a factor of 2–4 when compared to the 13 cm
Medical Physics, Vol. 34, No. 9, September 2007

circular QA aperture without bolus. The increased collimation present in the case of the patient specific aperture resulted in greater interaction of the primary proton beam with
the collimation material, leading to elevated doses outside
the treatment field. Dose equivalent values of approximately
4 and 2 mSv/Gy were found at 2.5 cm from the edge of the
primary beam for the patient specific aperture/bolus combination and the QA aperture, respectively. Sub-mSv readings
were detected at distances greater than 10 and 20 cm from
the field edge in the case of the QA aperture and patient
specific combination, respectively. At a distance of 60 cm
from the field edge the dose equivalent for the patient specific setup was 0.176 mSv/Gy, which would result in a total
dose equivalent at this point of 14 mSv assuming a total dose
delivery of 80 Gy to isocenter, which is the typical integral
dose used in patient treatments.
Figure 6 shows results of measurements that were completed to assess the change in dose equivalent as a function
of depth in a polystyrene phantom at 5 cm lateral distance
from the patient specific proton field 共series M1兲. For comparison, the central axis depth-dose distribution of the primary proton beam, as measured by a Markus chamber, is
also shown and normalized to the dose at isocenter 共100%兲.
Initial dose equivalent values at the surface of the phantom
decreased by 38% after traversing 5 cm of phantom material.
Figure 7 displays the lateral distance dependence of dose
equivalent at two different depths within the polystyrene
phantom 共measurement series M2兲. Measurements were
completed at the plateau region and the level of the SOBP.
The dose equivalent decreased with increasing distance from
the field edge, similarly to what was measured at the phantom surface 共Fig. 5兲, however with a more gradual falloff.
Moreover, the falloff is less pronounced at the level of the
SOBP compared to the shallower depth, which leads to a
convergence of the two curves at a lateral displacement from
the field edge of 20 cm. This would indicate that secondaries
produced inside the phantom contributed increasingly to the
dose equivalent.
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surement series M3兲, and also as a function of depth in polystyrene 共measurement series M1兲. The average quality factor
increased from 2 to 7 at a distance of 2.5 and 60 cm from the
field edge, respectively. Figure 9共b兲 shows that the average
quality factor past the SOBP remained relatively constant at
an approximate value of 6.5. In this region, high energy primary protons were not present and the radiation field comprised of relatively low energy neutrons produced both from
the beam-modifying/monitoring devices and within the
phantom. Figure 9共c兲 indicates that the average quality factor
does not change significantly in the proton plateau region,
with a stable value of approximately 2.5 registered. At the
level of the SOBP, the average quality factor increases to
values of 5–6.
IV. DISCUSSION
FIG. 7. Assessment of the dose equivalent as a function of lateral distance
from the field edge at different depths within the polystyrene phantom.

Figure 8 displays the dose equivalent past distal edge of
the SOBP in the polystyrene phantom 共measurement series
M3兲. The dose equivalent in the case of the typical prostate
treatment investigated here was 1.6 mSv/Gy at 0.6 cm from
the distal edge, and this value decreased exponentially with
increasing distance from the distal edge. Fitting an exponential function to this trend resulted in the following relationship for the dose equivalent in mSv:
H = 1.65e−0.1081x ,

共8兲

where x is the distance in cm from the distal edge.
The average quality factor is valuable as it provides information on the types and abundances of radiation present.
This information is presented in Fig. 9 as a function of lateral
distance from the treatment field edge measured at the surface of the anthropomorphic phantom, past the distal edge of
the SOBP in the homogeneous polystyrene phantom 共mea-

FIG. 8. Dose equivalent values past the distal edge of the SOBP.
Medical Physics, Vol. 34, No. 9, September 2007

In this work, we have utilized a microdosimeter based on
SOI technology to measure the depth and lateral distance
dependence of the dose equivalent for a passively scattered
proton beam used in a typical prostate cancer treatment. Unlike conventional TEPC devices, the SOI microdosimeter
comprises an array of truly microscopic detection elements.
This allows for faster data acquisition through the use of
multiple SVs, good spatial resolution, and placement inside
phantoms. The microdosimetry method also provides a more
accurate estimation of dose equivalent using an established
relationship between lineal energy and quality factor. This is
particularly advantageous in mixed radiation field measurements.
SOI microdosimetry has certain limitations that need to be
considered when evaluating the uncertainty of the measurements presented in this work. The lower level detection limit
of the SOI device is approximately 0.8− 1 keV/ m,
whereas the y values in the Q共y兲 distribution extend down to
0.1 keV/ m. This limitation does not produce a significant
error in the dose equivalent because the Q value is less than
1 in this region. The main source of error in these measurements arises from the TE conversion factor, which is derived
from the ratio of stopping powers. This factor covers a wide
range of recoil proton energies from 0.1–200 MeV; hence,
the value for each individual particle can lie from 0.5–0.8 as
shown in Fig. 10. Previous work with protons and alpha
particles has found best agreement using a value of 0.63. By
using this value, the systematic error introduced in the data
presented here may be up to about ±15%. Additional work,
including Monte Carlo simulations, is necessary to further
reduce this uncertainty for proton therapy applications.
Measurements in polystyrene provided information on the
change in dose equivalent 共Figs. 6 and 7兲 and average quality
factor 共Fig. 9兲 as a function of depth and lateral displacement
from the field edge. Figure 6 indicates that the initial dose
equivalent values at the surface of the phantom decreased by
38% after traversing 5 cm of phantom material. This leads to
the conclusion that many secondary particles produced
within the passive scattering and collimation system do not
penetrate to a great depth within the phantom. Such particles
are probably thermal neutrons; however, Monte Carlo simu-
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FIG. 9. Average quality factor values
for 共a兲 points lateral to the treatment
field edge at the surface of the anthropomorphic phantom; 共b兲 points past
the SOBP within the polystyrene
phantom; and 共c兲 as a function of
depth in polystyrene at 5 cm from the
primary field edge. In each case, the
aperture and bolus combination was
that for a typical prostate patient.

lations would be needed to determine this with certainty.
Figure 9共a兲 shows that at the surface of the phantom the
quality factor increases with increasing distance from the lateral field edge. This indicates that, close to the field edge,
scattered neutrons of higher energy and lower linear energy
transfer 共LET兲 made up a substantial portion of the dose
equivalent, however, further from the field edge lower energy
neutrons predominate resulting in higher average quality factors. In the region past the SOBP on the central beam axis the

FIG. 10. Ratio of proton stopping powers for silicon and tissue 共Ref. 25兲.
The region of interest in this case was approximately 0.1–200 MeV.
Medical Physics, Vol. 34, No. 9, September 2007

quality factor remains practically constant 关Fig. 9共b兲兴. In this
region, high energy primary protons are not present and the
radiation field comprises of relatively low-energy neutrons
produced both from the beam-modifying/monitoring devices
and within the phantom. Figure 9共c兲 indicates that at a lateral
distance of 5 cm from the field edge the average quality
factor did not change significantly in the proton plateau region, with a stable value of approximately 2.5 registered
while the dose equivalent decreases. At the level of the
SOBP, the average quality factor increased to values of 5–6
indicating the presence of higher LET particles, which are
predominantly slowing protons.
The SOI results presented here provide an estimate of the
dose equivalent both at the surface and at depth that a prostate cancer patient will experience during proton therapy.
They show that dose equivalent values are of the order of a
few mSv/Gy within 10 cm of the treatment volume 共Figs. 5
and 7兲 and appear to level off at about 0.2 mSv for larger
distances from the treatment volume 共Fig. 7兲. These dose
equivalent values compare favorably to those experienced by
patients from IMRT treatments2 and cone beam CT imaging
that is increasingly used for image guided radiation
therapy.26
It is important when applying existing technology to a
new mode of measurement to benchmark results against existing data in this field. Figure 11 illustrates the comparison
of results from other centers using different measurement
techniques. At the Midwest Proton Radiotherapy Institute
共MPRI兲, neutron doses were measured with a neutron bubble
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tering foils which contribute neutrons to the radiation field
outside the primary treatment field. The results from PSI,
HCL, and MPRI consisted of lower incident proton energies
than the measurements completed with the SOI microdosimeter, which may have a bearing on the results as lower incident proton energies have in turn lower cross sections for
inelastic reaction.
V. CONCLUSION

FIG. 11. Comparison of dose equivalent values determined using different
methods. In this figure results are presented from HCL 共Ref. 11兲, PSI 共Ref.
13兲, and MPRI 共Ref. 12兲 in comparison with results presented in this paper
using the SOI microdosimeter and the patient specific aperture/bolus combination 共Fig. 5兲.

detector and a passively scattered and modulated proton
beam of 12 cm range in water. The field size in this instance
was 10 cm in diameter with an 8 cm modulation delivered to
the midline of an anthropomorphic phantom. Measurements
were made as a function of distance from the proton field
edge within the phantom, with the detector situated within
the abdomen to determine the scattered neutron dose at the
location of a fetus. Measurements were completed for two
snout sizes 共10 and 20 cm兲, with the 20 cm results presented
here. The Harvard Cyclotron Laboratory 共HCL兲 data were
derived on the 160 MeV beamline used for patient treatments
utilizing Bonner spheres for the detection of neutrons. A Lucite phantom 共26 cm in diameter and 24 cm in length兲 represented the patient, while the primary proton radiation field
had a cross-sectional area of 5 ⫻ 5 cm2 and a range of 16 cm
with a modulation of 8.2 cm. The neutron dose equivalent
per unit proton absorbed dose was measured as a function of
vertical distance below isocenter. Finally, the data from the
Paul Scherrer Institute 共PSI兲 provide information on the secondary neutron dose delivered during a spot-scanning treatment. Again, this study utilized Bonner spheres as the radiation detection apparatus with an incident beam of 177 MeV
and no range shifter plates in the beam path. A water phantom with 0.5 cm thick Lucite walls was used to simulate the
patient. The values of effective neutron dose were measured
laterally from the water phantom at the level of the treatment
volume, not the surface of the phantom as in the case presented here.
Despite the difference in experimental conditions and
measurement techniques, the agreement between the data is
good. Of note, the equivalent doses measured with the spotscanning beam were consistently lower than the other data,
in particular at distances greater than 50 cm. This is consistent with the fact that the spot-scanning system does not
contain beam modifying devices such as apertures and scatMedical Physics, Vol. 34, No. 9, September 2007

This study has shown the applicability of the SOI microdosimeter in determining the dose equivalent outside proton
treatment fields, and has provided valuable information of
the dose equivalent both at the surface and at depth experienced by prostate cancer patients treated with protons. Further studies utilizing the SOI microdosimeter should be conducted with therapeutic proton fields generated with both
passive and active beam delivery techniques under otherwise
equivalent conditions and for different clinical treatment scenarios including pediatric cancers. It will also be useful in
such studies to compare the response of SOI detector to other
microdosimetric and neutron measurement techniques.
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